MedTrace Logo

Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)

NCT01121471 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2010-05-12

No results posted yet for this study

Summary

The purpose of this study is to determine the role of CLA as a complementary therapy to improve body composition, glucose tolerance, fasting plasma glucose and insulin, and hemoglobinA1c (HbA1c) in subjects with type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DIETARY_SUPPLEMENT

Conjugated Linoleic Acid (CLA)

6.4 g CLA/day, capsule form, for 16 week arms

DIETARY_SUPPLEMENT

Safflower OIl

8.0g/day safflower oil

Sponsors & Collaborators

  • Cognis

    collaborator INDUSTRY

  • Ohio State University

    lead OTHER

Principal Investigators

  • Martha A. Belury, PhD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121471 on ClinicalTrials.gov